

Mozambique Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Mozambique				
2. Grant number: 1518-MOZ-09a-X / 1819-MOZ-18c-X				
3. Date of Decision Letter: 21 December 2017				
4. Date of the Partnership Framework Agreement: 6 December 2013				
5. Programme title: New Vaccine Support (NVS), Measles-Rubella routine 1st dose (2018-2019) and 2 nd dose (2015-2017)				
6. Vaccine type: Measles-Rubella				
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED				
8. Programme duration¹: 2015 - 2019				
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)				
	2015-2017	2018	2019	Total ²
Programme Budget (US\$) (Measles-Rubella Routine, 2 nd Dose)	US\$ 1,079,485	0	0	US\$ 1,079,485
Programme Budget (US\$) (Measles-Rubella routine, 1st dose)	0	US\$ 721,500	US\$ 604,000	US\$ 1,325,500

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)³

Type of supplies to be purchased with Gavi funds in each year (Measles-Rubella routine 2 nd Dose)	2015-2017	2018	2019
Number of Measles-Rubella vaccines doses		0	0
Annual Amounts (US\$)	US\$1,079,485	US\$0	US\$0

Type of supplies to be purchased with Gavi funds in each year (Measles-Rubella routine, 1st dose)		2018	
Number of Measles-Rubella vaccines doses		1,148,600	
Annual Amounts (US\$)		US\$ 721,500	

11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

12. Self-procurement: Not applicable

13. Co-financing obligations for routine: Reference code: **1819-MOZ-18c-X-C**

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019
Number of vaccine doses	1,050,500	879,300
Value of vaccine doses (US\$)	640,781	
Total co-financing payments (US\$) (including freight)	\$660,000	\$552,500
Minimum number of doses to be financed from domestic resources	N/A	N/A
Minimum amount to be financed from domestic resources (US\$)	N/A	N/A

³ This is the amount that Gavi has approved.

14. Co-financing obligations for campaign: Not applicable	
15. Vaccine introduction grant (in US\$): US\$933,198 was disbursed on 5 July 2017	
16. Operational support for campaigns: Not applicable	
17. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
18. Financial clarifications: Not applicable	
19. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2017